相关临床试验
1284
103 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1853
Unknown
2
0.2%
已完成
794
61.8%
Enrolling By Invitation
6
0.5%
尚未招募
39
3.0%
No Longer Available
4
0.3%
终止
103
8.0%
招募中
159
12.4%
暂停
9
0.7%
Available
1
0.1%
撤回
109
8.5%
进行中（未招募）
58
4.5%
暂无批准数据
- The University of Florida has selected Duane A. Mitchell, MD, PhD, as the next Director of the UF Health Cancer Institute, effective September 21. - Dr. Mitchell is an internationally recognized physician-scientist who pioneered immunotherapy approaches for malignant brain tumors such as glioblastoma. - The institute earned National Cancer Institute designation in 2023 and has grown to over $57 million in total cancer grants. - Dr. Mitchell has secured more than $80 million in research support as a principal investigator and holds over 25 patents for cancer therapeutics.
- The U.S. Environmental Protection Agency approved CarriCea T1, a Huanglongbing (HLB)-resistant citrus rootstock developed by Soilcea using University of Florida research. - Citrus greening has slashed Florida's citrus industry by 95%, reducing production from 292 million boxes to 12 million and destroying more than 50 million trees. - CarriCea T1 works with the plant's own biology to naturally protect against HLB, and the resulting fruit is considered non-bioengineered by the USDA. - Soilcea reports more than 300,000 CarriCea T1 trees have already been ordered by growers across Florida.
- A University of Nottingham-led study published in BMC Biology identifies the lemon frost leopard gecko as a novel animal model for studying cancer, with tumors appearing naturally in approximately 80% of individuals. - Whole-genome sequencing revealed recurring genetic changes in gecko tumors that affect the same genes and biological pathways implicated in human cancers. - Unlike laboratory mice that require tumor induction, lemon frost geckos develop aggressive, metastatic tumors at a relatively young age, offering a rare window into natural cancer progression. - Researchers emphasize that studying species across the tree of life, including cancer-susceptible and cancer-resistant animals, could inspire new strategies for cancer prevention, detection, and treatment in humans.
- A proof-of-concept study found the monoclonal antibody ALT-100 significantly increased ventilator-free days in ARDS patients, averaging 21 days versus 14 for placebo. - The 15-patient randomized trial demonstrated ALT-100 reduced inflammatory markers and lowered organ failure scores with a safety profile comparable to placebo. - ALT-100 targets extracellular NAMPT, a master regulator of inflammation, putting brakes on excessive immune response without dampening infection-fighting ability. - ARDS affects an estimated 500,000 people annually in the U.S. and 2 million globally, with nearly 40% mortality and no FDA-approved therapies currently available.
- Chronic heavy alcohol use may speed up biological pathways linked to brain aging and Alzheimer's disease, according to new preclinical research presented at the Research Society on Alcohol annual meeting. - A mouse model study found that acetaldehyde, a toxic alcohol byproduct, reshapes the brain at the molecular level and contributes to Alzheimer's-like pathology, with sex-specific differences observed. - Separate research from Texas A&M University revealed that alcohol affects amyloid-beta and tau pathology in opposite ways within the corticostriatal circuit, challenging assumptions of uniform alcohol effects on Alzheimer's. - Experts caution that these preclinical findings do not prove causation in humans, but they reinforce the importance of discussing alcohol use as a modifiable risk factor for long-term cognitive health.
- Two independent studies published June 16 demonstrate that AI analysis of routine eye scans can predict risk factors for cardiovascular and neurological diseases, including Alzheimer's, heart failure, and Parkinson's. - University of Manchester researchers developed "Ret-AAE" using UK Biobank data from over 68,000 people, linking retinal features to genes involved in neurodegenerative pathways and cardiovascular function. - University of Florida scientists showed that machine learning analysis of retinal photographs from over 40,000 patients accurately predicted Alzheimer's risk factors such as blood pressure, smoking, alcohol use, and insomnia. - Both studies highlight the potential for widely available, low-cost high-street eye exams to serve as accessible health screening tools for disease prevention before symptoms appear.
- Researchers developed a novel imaging mass spectrometry method to map and quantify toxic lipids HexCer and psychosine across brain regions in a GLD mouse model, revealing spatial distribution patterns previously unknown. - Psychosine (HexSP) buildup was found to begin earlier than HexCer accumulation, with high concentrations in the cerebellum and posterior brain regions associated with disrupted myelin, neuronal damage, and inflammation. - The findings suggest that targeting stem cell therapies to the cerebellum, where fine motor skills are affected, could potentially deplete toxic psychosine levels and positively impact patient outcomes. - The study, published in the Journal of Lipid Research by Columbia University and University of Florida researchers, offers a new approach linking toxic lipid levels directly to neuronal damage over the disease course.
- A University of Florida study found glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia in a large patient record analysis. - Among patients already diagnosed with Alzheimer's disease and related dementias, glucosamine use was linked to a 25% increase in mortality risk. - Advanced imaging of human brain tissue and mouse models revealed an overactive sugar-tagging metabolic pathway that may explain glucosamine's potential harmful effects in the Alzheimer's brain. - Researchers emphasize the findings are preliminary and require validation in clinical trials, but raise important clinical questions about over-the-counter supplement use in at-risk populations.
- Vibrio vulnificus infections are moving northward along the U.S. Atlantic Coast at approximately 30 miles per year, with the northern boundary now reaching as far as Maine. - The CDC estimates approximately 80,000 vibriosis cases occur annually in the U.S., with vulnificus carrying a fatality rate of 15–50% depending on exposure route and patient health. - University of Florida researchers are developing a predictive model that can forecast high-risk coastal counties one month in advance, capturing 72% of cases in recent test runs. - Hurricane-driven flooding in 2022 and 2024 pushed brackish water inland, leading to 17 and 19 vulnificus deaths in Florida respectively, underscoring the link between extreme weather and infection spikes.
- The FDA has approved an IND application for the first randomized, double-blind, placebo-controlled clinical trial of mitragynine, the main psychoactive compound in kratom, in humans. - The NIH-sponsored Phase 1 study will enroll approximately 32 healthy volunteers with a recent history of opioid use to evaluate the safety, tolerability, and pharmacokinetics of a purified mitragynine formulation called MG001. - NIDA Director Nora Volkow described the trial as a "major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder." - The development signals a potential shift in federal regulatory posture, even as the FDA separately seeks to place the more potent kratom alkaloid 7-OH under Schedule I.
